Nicholas N. Vahanian
Geen lopende functies
Loopbaan van Nicholas N. Vahanian
Eerdere bekende functies van Nicholas N. Vahanian
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| LUMOS PHARMA, INC. | Directeur/Bestuurslid | 13-11-2015 | 11-11-2019 |
| Operationeel Directeur | 01-01-2001 | 21-12-2013 | |
| Hoofd Techniek/Wetenschap/O&O | 01-01-2001 | 13-11-2017 | |
| Oprichter | 04-06-1999 | 11-11-2019 | |
| President | 01-01-2009 | - | |
| LUMOS PHARMA, INC. | President | - | 27-09-2019 |
Opleiding van Nicholas N. Vahanian
| Virginia Commonwealth University | Undergraduate Degree |
| University of Notre Dame | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| President | 2 |
| Director/Board Member | 1 |
| Chief Operating Officer | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LUMOS PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
